In the analysis, 34 percent of rheumatoid arthritis patients receiving Rinvoq® achieved Clinical Disease Activity Index (CDAI) remission.
List view / Grid view
Novo Nordisk's Wegovy™ reduced body weight by 15.2 percent versus 2.6 percent with placebo in Phase IIIb study.
Birmingham Biotech and the University of Birmingham, UK, have signed a licensing agreement for an anti-viral nasal spray against COVID-19.
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent reduction in COVID-19 risks in Phase II/III study.
The new draft guidance has recommended dapagliflozin as an option for treating certain people with chronic kidney disease (CKD) in adults.
The Energize programme will allow 10 big pharma companies to engage with renewable energy suppliers and address their greenhouse gas emissions.
The Gates Biomanufacturing Facility announced a strategic agreement with Nkarta to manufacture Nkarta's investigational cell therapy NKX101.
Actinium's Actimab-A CLAG-M combination showed a 100 percent remission rate in relapsed or refractory acute myeloid leukaemia patients receiving 0.75 μCi/kg in Phase I study.
Roche and Novartis agree on the repurchase by Roche Holding Ltd of 53.3 million shares from Novartis worth 19 billion Swiss francs (CHF).
Gilead's Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.
Researchers review how miniaturised process analytical technologies (PAT), microfluidic affinity assays and microchip capillary electrophoresis, enhance bioprocess monitoring and control.
Tremfya inhibited radiographic progression and provided durable improvements in symptoms of axial involvement in psoriatic arthritis patients.
AstraZeneca will transfer its global rights to their two chronic obstructive pulmonary disease drugs Eklira and Duaklir to Covis Pharma.
The European Medicines Agency (EMA)'s pilot project will support not-for-profit organisations and academia in gathering evidence for the use of a drug in a new indication.
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.